Belgian drugmaker UCB plans $2 billion biologics plant near Atlanta, projecting 330 new manufacturing jobs
A major life sciences manufacturing project is planned for metro Atlanta
UCB, a Belgium-based biopharmaceutical company with an established presence in the Atlanta area, has announced plans to invest $2 billion in a new biologics manufacturing facility in the suburbs of Atlanta. The project is expected to add 330 jobs, positioning the site as one of the larger recent life sciences manufacturing announcements tied to the region’s growing advanced manufacturing base.
The planned facility is described as a state-of-the-art biologics plant, reflecting a broader industry shift toward expanding U.S.-based production capacity for complex medicines. Biologics manufacturing typically involves tightly controlled processes and specialized equipment, and projects of this scale often require multi-year construction and extensive validation before commercial production can begin.
Why biologics manufacturing capacity is a strategic focus
UCB has framed the investment as part of an effort to strengthen supply chain resilience and to align manufacturing capacity with its product portfolio and pipeline. For biopharmaceutical companies, domestic capacity can reduce logistical complexity and support continuity for high-value medicines that depend on consistent quality systems and tightly managed cold-chain requirements.
The announcement also comes as competition intensifies among U.S. regions for advanced manufacturing projects tied to pharmaceuticals, medical technologies, batteries, and other capital-intensive sectors. In Georgia, recent years have included multiple large industrial recruitment efforts, and state and local governments have maintained incentive frameworks aimed at attracting projects that combine significant capital investment with sustained job creation.
How Georgia’s incentive landscape can intersect with large projects
Georgia’s incentive toolbox includes programs that can reward qualifying projects based on investment, payroll, and job creation thresholds, including credits tied to new facilities and job growth. While the specific package associated with UCB’s planned plant has not been detailed in the announcement, projects of this size frequently evaluate eligibility for state tax credits and local arrangements during site selection and development.
What to watch as the project moves from announcement to execution
Site and timeline details: large biomanufacturing projects typically proceed in phases, from site preparation to construction, equipment installation, and regulatory validation.
Workforce requirements: biologics production roles often require specialized training in quality systems, sterile operations, engineering, and supply chain management.
Regional supply chain impacts: projects can generate follow-on demand for contractors, equipment suppliers, logistics providers, and specialized services needed for regulated manufacturing environments.
The company has described the planned plant as a new biologics manufacturing facility intended to expand U.S. capacity and support a more resilient supply chain.
If delivered as outlined, the investment would add a high-profile biomanufacturing asset to metro Atlanta’s economy and further strengthen Georgia’s position in advanced manufacturing beyond the state’s better-known automotive and battery supply chain growth.